MX2023000760A - Composiciones subcutaneas del inhibidor de la telomerasa y metodos para su uso. - Google Patents

Composiciones subcutaneas del inhibidor de la telomerasa y metodos para su uso.

Info

Publication number
MX2023000760A
MX2023000760A MX2023000760A MX2023000760A MX2023000760A MX 2023000760 A MX2023000760 A MX 2023000760A MX 2023000760 A MX2023000760 A MX 2023000760A MX 2023000760 A MX2023000760 A MX 2023000760A MX 2023000760 A MX2023000760 A MX 2023000760A
Authority
MX
Mexico
Prior art keywords
telomerase inhibitor
subcutaneous
methods
inhibitor compositions
same
Prior art date
Application number
MX2023000760A
Other languages
English (en)
Inventor
Patrick Murphy
Anil KAPUR
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of MX2023000760A publication Critical patent/MX2023000760A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01036—Hyaluronoglucuronidase (3.2.1.36)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

Los aspectos de la descripción incluyen composiciones inhibidoras de la telomerasa formuladas para administración subcutánea. Las composiciones de acuerdo con determinadas modalidades incluyen una enzima hialuronidasa y un inhibidor de telomerasa que tiene un oligonucleótido y un resto lipídico unido al extremo 5' y/o 3' del oligonucleótido. También se describen métodos para administrar por vía subcutánea las composiciones inhibidoras de la telomerasa, tales como en el tratamiento de una neoplasia. También se proporcionan kits que tienen o no tienen un inyector subcutáneo.
MX2023000760A 2020-07-17 2021-07-15 Composiciones subcutaneas del inhibidor de la telomerasa y metodos para su uso. MX2023000760A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063053455P 2020-07-17 2020-07-17
US202063128708P 2020-12-21 2020-12-21
PCT/US2021/041755 WO2022015935A2 (en) 2020-07-17 2021-07-15 Subcutaneous telomerase inhibitor compositions and methods for using same

Publications (1)

Publication Number Publication Date
MX2023000760A true MX2023000760A (es) 2023-02-13

Family

ID=79556008

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000760A MX2023000760A (es) 2020-07-17 2021-07-15 Composiciones subcutaneas del inhibidor de la telomerasa y metodos para su uso.

Country Status (11)

Country Link
US (1) US20220168403A1 (es)
EP (1) EP4182031A2 (es)
JP (1) JP2023534295A (es)
KR (1) KR20230041707A (es)
CN (1) CN115776909A (es)
AU (1) AU2021309963A1 (es)
CA (1) CA3181682A1 (es)
IL (1) IL299205A (es)
MX (1) MX2023000760A (es)
TW (1) TW202218668A (es)
WO (1) WO2022015935A2 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125858B2 (en) * 1999-12-28 2006-10-24 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
CA2517145C (en) * 2003-03-05 2017-08-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2771301B1 (en) * 2011-10-25 2017-12-20 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2013102144A2 (en) * 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
US9375485B2 (en) * 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
UA117141C2 (uk) * 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
EP3065828B1 (en) * 2013-11-06 2019-01-09 Mayo Foundation for Medical Education and Research Methods and materials for treating hematological malignancies

Also Published As

Publication number Publication date
JP2023534295A (ja) 2023-08-08
US20220168403A1 (en) 2022-06-02
WO2022015935A2 (en) 2022-01-20
EP4182031A2 (en) 2023-05-24
CA3181682A1 (en) 2022-01-20
KR20230041707A (ko) 2023-03-24
WO2022015935A3 (en) 2022-03-17
TW202218668A (zh) 2022-05-16
IL299205A (en) 2023-02-01
AU2021309963A1 (en) 2023-02-02
CN115776909A (zh) 2023-03-10

Similar Documents

Publication Publication Date Title
UA85055C2 (ru) Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
BR112022025583A2 (pt) Conjugado de molécula de ligação à superfície celular e análogo de camptotecina, composto conjugável, célula de tumor, composição farmacêutica, agente quimioterapêutico, e, agentes sinergísticos
WO2000063364A3 (en) Methods and compositions for inhibiting the function of polynucleotide sequences
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2003211149A1 (en) Antimicrobial therapeutic compositions and methods of use
MX339658B (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa.
MX2021011948A (es) Compuestos con actividad antitumoral contra células cancerígenas que llevan inserciones de exon 20 effr o her2.
MX2008000838A (es) Composiciones y metodos para tratar infeccion bacteriana gram positiva en un sujeto mamifero.
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
MX2023000760A (es) Composiciones subcutaneas del inhibidor de la telomerasa y metodos para su uso.
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
WO2019139956A3 (en) Prevention and treatment of organ fibrosis
EP4295917A3 (en) Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
WO2021216687A9 (en) Peptides for the treatment of covid-19
WO2003106640A3 (en) CELL TARGETING METHODS AND COMPOSITIONS
PL378713A1 (pl) Kompozycje przeciwpierwotniakowe, zawierające diklazuryl
HUP0103660A2 (hu) Mikróbaeredetű hialuronsavbontó enzimet tartalmazó gyógyászati készítmény
WO2022118016A3 (en) Enzyme inhibitors
MX2023007734A (es) Composiciones de anticuerpos y metodos de uso de las mismas.
EP4353232A3 (en) Composition comprising trabectedin and an amino acid
EP1663280A4 (en) METHOD FOR IMPROVING HEMATOPOIESE
CR20230258A (es) Compuestos y composiciones de moléculas pequeñas
MX2022012982A (es) Agentes inmunoestimulantes en combinación con inhibidores de la angiogénesis.
WO2023172497A3 (en) Compounds, compositions, and methods for treating, ameliorating, and/or preventing cocaine use disorder
ATE439857T1 (de) Lipoglykan zusammensetzungen und methoden zur behandlung von parasitischen infektionen